Latigo Biotherapeutics Inc.(LTGO:US)
Market Cap$842.14M
Key Metrics
Price$14
Revenue (TTM)-
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-
EBITDA (TTM)-
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$42.18M
Total Assets$50.58M
Net Assets-$252.58M
Total Debt$554K
Key Metrics
Price$14
Revenue (TTM)-
Holders Revenue (TTM)-
Gross Profit (TTM)-
Earnings (TTM)-
EBITDA (TTM)-
Op. Margin (TTM)-
Dividend Yield-
Holders Yield-
Cash on hand$42.18M
Total Assets$50.58M
Net Assets-$252.58M
Total Debt$554K
Financials
| Name | Jun 30, 2026 | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Cost of Revenue | - | - | - |
Gross Profit | - | - | - |
| $25.81M | $23.44M | $21.51M | |
| Research and Development | $21.23M | $17.63M | $18.69M |
| Selling, General, and Administrative | $4.58M | $5.8M | $2.82M |
| Other Operating Expenses | - | - | - |
Operating Income | -$25.81M | -$23.44M | -$21.51M |
| $11K | $475K | $560K | |
| Non-Operating Interest Income | $264K | $474K | $517K |
| Non-Operating Interest Expense | $251K | - | - |
| Other Income/Expense | -$2K | $1K | $43K |
Income Before Tax | -$25.8M | -$22.96M | -$20.95M |
Income Tax | - | - | - |
Net Income | -$25.8M | -$22.96M | -$20.95M |
Minority Interests | - | - | - |
Preferred Stock Dividends | - | - | - |
Net Income to Common | -$25.8M | -$22.96M | -$20.95M |
Shares Outstanding (Basic) | 60.15M | - | - |
Shares Outstanding (Diluted) | 60.15M | - | - |
EPS (Basic) | -$0.43 | - | - |
EPS (Diluted) | -$0.43 | - | - |
EBIT | -$25.55M | -$23.44M | -$21.51M |
EBITDA | -$25.49M | -$23.39M | -$21.45M |